Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Botanix Pharmaceuticals is a clinical-stage dermatology biotech developing cannabinoid-based topical therapies, with lead asset Sofdra (sofpironium bromide) targeting primary axillary hyperhidrosis and a pipeline including acne and atopic dermatitis candidates. The company operates with no commercial revenue, burning approximately $30M annually while advancing FDA regulatory pathways. Stock performance is driven entirely by clinical trial readouts, regulatory milestones, and capital raise events rather than operational fundamentals.
Botanix operates a classic biotech development model: raise capital through equity offerings, advance clinical programs through FDA trials, then monetize via direct commercialization or partnership deals. The company's synthetic cannabinoid platform (Permetrex delivery technology) targets dermatological conditions with limited competition. Value creation hinges on achieving FDA approval for Sofdra, which would enable prescription revenue capture in the primary axillary hyperhidrosis market. With 4.0x current ratio and minimal debt (0.40 D/E), the company maintains runway through 2026-2027 based on current burn rate, but will likely require additional capital raises before commercialization.
FDA regulatory decisions and milestone achievements for Sofdra NDA submission and approval timeline
Clinical trial data readouts for pipeline programs (acne, atopic dermatitis indications)
Capital raise announcements and dilution events given negative $30M annual cash flow
Partnership or licensing deal announcements that validate platform technology or provide non-dilutive funding
Competitive developments in hyperhidrosis treatment landscape (Qbrexza, Botox alternatives)
FDA approval risk for Sofdra remains binary event - any Complete Response Letter or approval delay would eliminate near-term value thesis and force capital raise at depressed valuation
Cannabinoid regulatory pathway uncertainty given evolving FDA stance on cannabis-derived compounds, potentially creating approval hurdles despite synthetic formulation
Dermatology market consolidation and payer reimbursement pressure could limit commercial opportunity even with approval, particularly for non-life-threatening conditions like hyperhidrosis
Qbrexza (glycopyrronium) already approved for primary axillary hyperhidrosis creates established competitor with physician familiarity and payer coverage
Botox injections and iontophoresis devices offer alternative treatment modalities that may limit Sofdra market penetration despite topical convenience advantage
Larger dermatology players (LEO Pharma, Galderma) could enter market with superior commercial infrastructure if Botanix validates opportunity
Negative $30M annual operating cash flow with approximately $40M cash position (estimated from 4.0x current ratio) implies imminent capital raise need within 12-18 months
Stock down 87.5% over one year severely limits equity financing options - any capital raise at current levels would be massively dilutive to existing shareholders
No debt capacity given pre-revenue status and negative equity returns (-99.4% ROE) means equity dilution is only funding path absent partnership deal
low - Clinical-stage biotechs are insulated from GDP cycles as they generate no revenue and operate on pre-determined trial timelines. However, severe recessions can impact ability to raise capital at favorable valuations, forcing dilutive financings. The company's 87.5% one-year decline reflects biotech sector weakness and risk-off sentiment rather than economic fundamentals.
High sensitivity through valuation mechanism rather than operations. Rising rates compress biotech valuations by increasing discount rates applied to distant future cash flows (Sofdra revenue potentially 2027+). The 10-year Treasury yield directly impacts how investors value speculative, long-duration assets. Higher rates also increase opportunity cost of holding cash-burning equities versus risk-free alternatives. No direct interest expense impact given minimal debt.
Moderate - While the company carries low debt (0.40 D/E), access to capital markets is critical for survival. Tightening credit conditions and risk-off sentiment in biotech funding markets directly threaten ability to raise necessary capital before commercialization. High-yield credit spreads serve as proxy for risk appetite that determines equity financing availability and terms.
growth - Pure speculation on binary FDA approval outcome attracts risk-tolerant biotech specialists and retail momentum traders. No value investors given negative earnings and no dividend. The 87.5% decline has eliminated most momentum players, leaving only deep-value biotech funds betting on approval surprise or takeover. Volatility profile is extreme given clinical-stage binary events and low float.
high - Clinical-stage biotechs exhibit 60-80% annualized volatility driven by binary trial readouts and regulatory decisions. The -58% six-month and -30% three-month returns demonstrate ongoing downward volatility as approval timeline extends and capital raise pressure builds. Any FDA news or trial data creates 20-40% single-day moves in either direction.